EU drug regulator reviewing French/British Vidprevtyn vaccine
The European Medicines Agency, the drug regulator of the European Union, has begun a real-time review of another vaccine against the coronavirus. The Vidprevtyn vaccine, which is protein-based, was developed by by French drugmaker Sanofi and the UK’s GlaxoSmithKline. it is the fifth vaccine to undergo a review, which comes after results from early state clinical trials in adults. Late-stage global trials began in May. The four vaccines authorized for use in the EU by the regulator are Pfizer, Moderna, AstraZeneca and Johnson & Johnson.